MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-DL-10-0003330
Getwell Pharma India Private Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹56.34 Cr
▲ 76% YoY
Net profit · FY 2025
₹2.04 Cr
Net margin 3.6%
EBITDA · FY 2025
₹9.98 Cr
EBITDA margin 17.7%
Authorised capital
₹34.75 Cr
Registered with MCA
Paid-up capital
₹32.75 Cr
Issued & subscribed
Open charges
₹42.19 Cr
Secured borrowings
Company age
9 yrs
Est. 2017
Employees · EPFO
201
Provident fund records
About Getwell Pharma India Private Limited
Data last updated:
Getwell Pharma India Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 January 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24290DL2017PTC310791. Its GSTIN is 07AAGCG6543D1ZQ (Delhi). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹34.75 Cr and a paid-up capital of ₹32.75 Cr. It was formerly known as Getwell Pharma Innovations Private Limited. It is led by directors including Manas Tandon and Mini Tandon.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Flat No 721, Sector 19 Pocket 3, Delhi, India – 110075.
As per the financials filed for FY 2025, the company reported a revenue of ₹56.34 Cr, a growth of 76% compared to the previous year. For the same year it recorded a net profit of ₹2.04 Cr (net margin 3.6%) and EBITDA of ₹9.98 Cr (EBITDA margin 17.7%).
The company has about 201 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Getwell Oncology. As per MCA filings, the company has open charges of ₹42.19 Cr on record. The company has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹11.48 Cr; the latest was in March 2022. Its 10 peer companies in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 5 larger and 5 smaller; the largest is Ataraxia Pharma Private Limited with revenue of ₹108.65 Cr. The company has 6 MSME Form 1 returns on record between 2021 and 2024, listing 66 overdue payments to 38 micro and small suppliers.
Getwell Pharma India Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-10-0003330). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website getwelloncology.com.
Company details
CIN U24290DL2017PTC310791
Registration Number 310791
Incorporation Date 19 January 2017
ROC Delhi
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-DL-10-0003330
Name history
Getwell Pharma India has undergone 3 name changes throughout its history. The company was previously known as Getwell Pharma Innovations Private Limited, Getwell Pharma India Private Limited, and Getwellpharma India Private Limited. The current legal name is Getwell Pharma India Private Limited.
| Company Name | Status |
|---|---|
| Getwell Pharma India Private Limited | Current |
| Getwell Pharma Innovations Private Limited | Previous |
| Getwellpharma India Private Limited | Previous |
Recognitions & Rankings of Getwell Pharma India
Contact details
Getwell Pharma India Private Limited's registered office is in Delhi, Delhi. Its website is getwelloncology.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFlat No 721, Sector 19 Pocket 3, Delhi, India – 110075
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Getwell Pharma India Private Limited, buy the company report.
Comprehensive company report
Getwell Pharma India Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Getwell Pharma India operates one associated brand: Getwell Oncology. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturing and supplying anti-cancer drugs with a focus on oncology pharmaceuticals in India. | getwelloncology.com |
Business activity
The main business activity of Getwell Pharma India is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Getwell Pharma India Private Limited, buy the company report.
Financials of Getwell Pharma India Private Limited
FY 2024 filings availableGetwell Pharma India Private Limited reported revenue of ₹56.34 Cr (up 76% YoY) for FY 2025.
Revenue · FY 2025
₹56.34 Cr ▲ 76%
Net profit · FY 2025
₹2.04 Cr margin 3.6%
EBITDA · FY 2025
₹9.98 Cr margin 17.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 76%
EBITDA CAGR growth
1 year
▲ 196%
Revenue rose 76% in the latest year. EBITDA rose 196% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹9.98 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.04 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.7% | ||||
| Net Profit Margin | 3.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Getwell Pharma India Private Limited, buy the company report.
Board of directors of Getwell Pharma India Private Limited
Getwell Pharma India has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manas Tandon | Director | 19 Jan 2017 | 9 Years 9 Months | Current |
| Mini Tandon | Director | 19 Jan 2017 | 9 Years 9 Months | Current |
| Rakesh Dwivedi | Director | 16 Oct 2023 | 3 Years 0 Months | Current |
| Prerna Tandon Also directs: Getwell Research Foundation | Director | 15 Apr 2022 | 4 Years 6 Months | Current |
Peer comparison
Getwell Pharma India Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ataraxia Pharma Private Limited | ₹108.65 Cr (FY 2025) | 582.0% | Aurangabad, Maharashtra, India | |||
| Actaviaa Biotech Private Limited | ₹91.8 Cr (FY 2025) | 10687.0% | Delhi, India | |||
| Gluconate Health Ltd | ₹70.08 Cr (FY 2020) | 7.0% | Kolkata, West Bengal, India | |||
| Renol Polychem Limited | ₹62.56 Cr (FY 2025) | 859.0% | Rajkot, Gujarat, India | |||
| Shankus Pharma Private Limited | ₹62.35 Cr (FY 2025) | -20.0% | Mehsana, Gujarat, India | |||
| Getwell Pharma India Private Limitedthis company | ₹56.34 Cr (FY 2025) | ₹2.04 Cr | 3.6% | 76.0% | 201 | Delhi, India |
| RDR Pharmachem Private Limited | ₹52.01 Cr (FY 2025) | 23.0% | Mumbai, Maharashtra, India | |||
| Clean Fino-Chem Limited | ₹50.17 Cr (FY 2025) | 739.0% | Pune, Maharashtra, India | |||
| Medistep Healthcare Limited | ₹49.66 Cr (FY 2025) | 57.0% | Ahmedabad, Gujarat, India | |||
| Biopol Chemicals Limited | ₹49.22 Cr (FY 2025) | 174.0% | Ahmedabad, Gujarat, India | |||
| Intercos India Private Limited | ₹48.34 Cr (FY 2025) | 118.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Getwell Pharma India Private Limited, buy the company report.
Auditor
Getwell Pharma India Private Limited is audited by DSP & ASSOCIATES for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DSP & ASSOCIATES | FY 2022 | 006791N |
Shareholding
The shareholding of Getwell Pharma India Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Getwell Pharma India Private Limited, buy the company report.
Charges & borrowings
Open charges
₹42.19 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 13 Nov 2024 | 101010153 | State Bank of India | ₹90 Lakh | Open | |
| 23 Feb 2024 | 100884408 | State Bank of India | ₹5.8 Lakh | Open | |
| 03 Aug 2023 | 100787535 | Hdfc Bank Limited | ₹14.4 Lakh | Open | |
| 31 May 2022 | 100584572 | State Bank of India | ₹3.5 Cr | Open | |
| 22 Jul 2020 | 100422318 | State Bank of India | ₹1.4 Cr | Open |
To see the full charge records of Getwell Pharma India Private Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Getwell Pharma India Private Limited has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹11.48 Cr; the latest was in March 2022.
Total deals
4
Funding rounds
2
Rights issue
1
Secondary share transfer
1
Disclosed funding
₹11.48 Cr
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Funding round | ₹1.5 Cr | Investors: Getwell International FZC LLC |
| Jan 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2021 | Rights issue | ₹5 Cr | Investors: 3 individuals |
| Oct 2018 | Funding round | ₹9.98 Cr | Investors: 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Getwell Pharma India Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
Credit ratings & regulatory alerts
Getwell Pharma India Private Limited was last rated by Care on 26 Aug 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 26 Aug 2022 |
To see the full credit ratings and regulatory alerts of Getwell Pharma India Private Limited, buy the company report.
MSME payment delays
Getwell Pharma India Private Limited has 6 MSME Form 1 returns on record between 2021 and 2024, listing 66 overdue payments to 38 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 38)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Kay Art Printers Private Limited | |||
| Ketan Pharma | |||
| an individual supplier | |||
| Pachas Consultants LLP | |||
| Mac-Chem Products (India) Private Limited |
To see the full MSME payment records of Getwell Pharma India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Getwell Pharma India Private Limited has a workforce of 201 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Employee count
201
Active EPFO establishments
1
Employee growth
12.3%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 201 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 |
To see the full employee and EPFO history of Getwell Pharma India Private Limited, buy the company report.
GST
Getwell Pharma India has 3 GST registrations: 3 active.
Total GSTINs
3
Active
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAGCG6543D1ZQ | Delhi | Active | 16 Oct 2017 |
| 06AAECM0720G1ZZ | Haryana | Active | 01 Jul 2017 |
| 06AAGCG6543D1ZS | Haryana | Active | 27 Feb 2018 |
To see the full GST registrations and return filing status of Getwell Pharma India Private Limited, buy the company report.
Recent activity
Getwell Pharma India Private Limited has 8 board changes on record since 2017: 4 appointments and 4 cessations. The latest: Prerna Tandon ceased to be Additional Director on 29 Sep 2024.
Charges
A charge with State Bank Of India amounted to Rs. 0.90 Cr with Charge ID 101010153 was registered on 13 Nov 2024.
Charges
A charge with State Bank Of India of Rs. 36.19 Cr registered on 18 Jun 2018 with Charge ID 100228775 was modified on 22 Oct 2024.
AGM
Getwell Pharma India Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Ceased
Prerna Tandon ceased to be Additional Director.
Ceased
Rakesh Dwivedi ceased to be Additional Director.
Filing
Getwell Pharma India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Charges
A charge with State Bank Of India amounted to Rs. 0.06 Cr with Charge ID 100884408 was registered on 23 Feb 2024.
Appointed
Rakesh Dwivedi was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.14 Cr with Charge ID 100787535 was registered on 03 Aug 2023.
Charges
A charge with State Bank Of India amounted to Rs. 3.50 Cr with Charge ID 100584572 was registered on 31 May 2022.
Appointed
Prerna Tandon was appointed as Director.
Ceased
Rajiv Tandon ceased to be Director.
6 earlier events are in the company report.
Frequently asked questions
Getwell Pharma India is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 January 2017 (9+ years old) and is registered under CIN U24290DL2017PTC310791.
Getwell Pharma India has 4 current directors:
- Manas Tandon - Director
- Mini Tandon - Director
- Rakesh Dwivedi - Director
- Prerna Tandon - Director
The latest financial statements of Getwell Pharma India on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Getwell Pharma India is 07AAGCG6543D1ZQ, registered in Delhi. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 06AAECM0720G1ZZ (Haryana), 06AAGCG6543D1ZS (Haryana).
The CIN (Corporate Identification Number) of Getwell Pharma India is U24290DL2017PTC310791. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Getwell Pharma India was incorporated on 19 January 2017, making it 9+ years old. It is registered with the Registrar of Companies, Delhi.
Getwell Pharma India has 4 deals on record (2 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹11.48 Cr; the latest was in March 2022.
The peers of Getwell Pharma India by revenue are Ataraxia Pharma Private Limited, Actaviaa Biotech Private Limited, Gluconate Health Ltd, Renol Polychem Limited, Shankus Pharma Private Limited and 5 more, all in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Prerna Tandon ceased to be Additional Director on 29 Sep 2024. Rakesh Dwivedi ceased to be Additional Director on 29 Sep 2024. Rakesh Dwivedi was appointed as Director on 16 Oct 2023. Getwell Pharma India has 8 board changes on record in total.
Yes, Getwell Pharma India is registered as a medium enterprise under Udyam registration (number: UDYAM-DL-10-0003330).
Getwell Pharma India has 6 MSME Form 1 returns on record between 2021 and 2024, listing 66 overdue payments to 38 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Getwell Pharma India can be reached through the website getwelloncology.com. Its registered office is in Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages